Pharma giant asks state and federal regulators to stop sales of retatrutide, but enforcement bandwidth may be slight

As soon as Lilly put out its Aug. 12 press release announcing six lawsuits against a mix of online sellers, medispas and compounding pharmacies it alleges are selling knock-offs of its years-from-market retatrutide weight loss drug, and revealed that it had referred 200 more “individuals and entities” to the federal regulators and state attorneys general, Dustin Robinson’s phone started ringing.

A founding partner at LumaLex Law, Robinson represents companies in the peptide trade and all of them were anxious about the announcement. “Everyone istrying to make sense of this,” he says. Making sense, he says, requires both a big picture view and a narrow focus. Lilly wants to send a message—"It’s a PR stunt in some respects,” Robinson says—but few people believe the FDA and state investigators are going to start raiding medispas and compounding pharmacies next week.

Let’s dive in.

The intent of the press release appears to be taking retatrutide off the menu because the risk may have gone up, at least for that one peptide, says Robinson. “My message to anyone selling retatrutide right now, is that the enforcement posture has definitely tightened up, and they should strongly consider pulling any products.”

After Lilly’s press release, the six peptides that the Compounding Pharmacy Advisory Committee recommended be legally manufactured and distributed became not a safe bet, but perhaps a safer bet. “You can't really lump all the peptides together,” Robinson says. “They're all treated differently.”

What regulators hear from the press release may be more nuanced than that, possibly including actions related specifically to retatrutide sales. Ashish Talati, a well-known lawyer in dietary supplements whose work increasingly includes peptides, predicts the FDA will “triage” the 200 referrals Lilly made. If any actions are taken, they will most likely target bigger operations. FDA’s enforcement is “risk-based,” Talati says. “The agency is likely to prioritize cases involving more significant distribution, aggressive claims, questionable sourcing or manufacturing practices, or other potential safety concerns. So, even where FDA may view a number of the referred entities as technically violating the law, that does not necessarily mean each one will warrant formal enforcement action.”

How people selling peptides assess where they fall on the FDA’s prosecution pecking order will vary, Robinson points out. And peptide sellers know that. “It hasn't really scared many people off because the upside and the money people are making kind of outweighs the risk of simply getting a warning letter."

Rick Collins, another lawyer whose workload is shifting from supplements to peptides, calls it misguided for anybody to assume that FDA actions will end with slaps on the wrists. Collins noted on LinkedIn that assuming that “warning letters are the only tool in FDA's toolbox is a dangerous misconception (as many of my clients have learned too late). There's a branch of FDA with guns and badges that can arrive with a search warrant. Statistically, it's made a tiny dent in the market. But it's about using limited resources to make a few examples.”

Collins offered speeding on the highway as an analogy. Authorities use the threat of enforcement to control how fast people are willing to drive, he explaind. “The highway patrol knows it lacks the resources to target everyone, and the vast majority will never be ticketed. But a small percent will be. And in the case of unapproved drug sales, the potential consequences are far more serious than those for speeding.”

How speed limits are set and enforced, however, varies at a local level, as anybody who has seen a patrol car lurking just inside a small town’s city limits sign knows. With the practice of medicine enforced at the state level, enforcement regarding retatrutide and other peptides will happen state by state. Pradeep Albert, CEO of the American Academy of Peptide Medicine contends that location may be the biggest takeaway from Lilly’s press release. Prosecutors will be studying the map, he says. “If you're getting referred to in Indiana where Eli Lilly headquarters is, or if you're in Alabama where they're building a giant plant, you're going to be in trouble. But let's say you live in Alaska. Frankly, you're probably going to be okay because they don't really care about you."

Melissa Mena-Schneller, a former Lilly employee who now consults on drug development at MeLi MeThoDS, says enforcement by the state and federal authorities is not what will really matter in the end. The FDA knows it doesn’t have the resources to go after the “200 entities and individuals” in Lilly’s press release. It doesn’t have to, she explains.

Mena-Schneller’s theory holds that just as Lilly holds the patent on retatrutide, other companies will pick up patents on variations of the other popular peptides. Enforcement will happen by lawsuit, not by state or regulators knocking on the doors of compound pharmacists. "They're saying ‘We're handing it off to the pharmaceutical companies to sue you, so that you don't just get shut down; you're left with mass amounts of debt."

Mena-Schneller predicts Talati’s contention that the bigger and more flagrant violators will be targeted first by FDA actions will hold equally true at the lawsuit level. Lilly’s six lawsuits illustrate that, she explains.

"Do they have the bandwidth for all these companies? Probably not, because there are so many. But what they will do is make examples, and it's not even hypothetical anymore."

That doesn’t mean smaller operations are operating risk-free, however. Mena-Schneller says she tells people and companies who believe they are flying under the radar that the risks could be even bigger. Deep pockets make companies targets, but deep pockets are also insulation against financial ruin. "If for some reason you happen to make it into the eyesight of the FDA or the patent attorneys, you're going to be at a way bigger risk because you will not be able to afford that lawsuit like some of the bigger companies will."

Anybody playing the game should know that flying under the radar is difficult when the radar becomes uneven. Many predict that Health and Human Services Secretary Robert F Kennedy, who has expressed support for peptides, will declare enforcement discretion that would take peptides off the target list. That may be true, but Robinson warns it could shift in the other direction at a moment’s notice.

“Laws take a long time to change, whereas the enforcement posture could change quickly,” Robinson says. "The thing that will scare people the most is that the DOJ is involved, right? If actually goes criminal. If they really want to send a message to the industry, the DOJ would be the right path to take. If you start to see prosecution, you know that risk-benefit analysis shifts quite a bit."

Nutrition Spotlight

 Dr. Ann Monis, CEO, Transformative Healhcare Soluions

Peptide: PBC-157 

What nutritional challenges and deficiencies can the use of BPC-157 cause? There is a limited amount of evidence relating to negative impacts of human consumption of BPC-157; however, it is important to note that research related to human consumption of BPC-157 is still ongoing. Of greater concern to me surrounding the topic of peptides is the fallacy that peptide consumption can be used as a replacement for the necessary macro and micronutrients that serve as the baseline for recovery, rather than as a supplemental recovery aid for which it is intended.

What should users of BPC-157 be thinking about in their diet? Regardless of peptide use, prioritizing the essentials is always necessary; it becomes even more relevant alongside BPC-157 consumption. Think about maintaining adequate hydration, eating a high-protein, nutrient-dense diet of primarily whole foods, all the while ensuring sufficient overall caloric intake. If the objective of peptide utilization is to support tissue recovery, a diet lacking enough protein or restricting calories aggressively would be counterintuitive in working towards that goal. BPC-157, or any peptide for that matter, should never replace the fundamentals we already recognize as being pivotal for maintaining a healthy body.

Which supplements should they consider taking? Before designing a supplementation stack, lab results and other clinical data that point to legitimate dietary needs or deficiencies should be considered. A few examples of commonly supplemented vitamins and micronutrients include vitamins C and D, zinc and magnesium, proteins and amino acids; however, it is important to note that more is not necessarily better. There is such a thing as too much, and these come with a myriad of consequences. The goal here is to balance the understanding of what the body has enough of and only to supplement what it requires, without adding things unnecessarily just because peptides are being used.

How can those supplements improve the outcome from their peptide therapy? I would pose this differently: BPC-157 and related peptide substances may deliver a physiological signal for tissue repair; however, the body still requires the building blocks necessary for executing this repair. Ensuring adequate protein intake, correcting for nutritional deficiencies, and maintaining metabolic health overall may contribute to a better biological atmosphere that supports recovery. However, this is a pointedly different claim than stating that there is any one supplement or supplement stack that directly improves peptide therapy outcomes.